Citation: | SHEN Hong, ZHU Lei, ZHANG Lu. Exploration of Treatment Strategies with Integrated Traditional Chinese and Western Medicine for Crohn's Disease under the Background of Biological Agents[J]. Journal of Nanjing University of traditional Chinese Medicine, 2022, 38(8): 739-742. doi: 10.14148/j.issn.1672-0482.2022.0739 |
[1] |
NG SC, SHI HY, HAMIDI N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies[J]. Lancet, 2017, 390(10114): 2769-2778. doi: 10.1016/S0140-6736(17)32448-0
|
[2] |
ZHAO J, NG SC, LEI Y, et al. First prospective, population-based inflammatory bowel disease incidence study in mainland of China[J]. Inflamm Bowel Dis, 2013: 1.
|
[3] |
ZENG ZR, ZHU ZH, YANG YY, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: A prospective population-based study[J]. J Gastroenterol Hepatol, 2013, 28(7): 1148-1153. doi: 10.1111/jgh.12164
|
[4] |
YANG H, LI YM, WU W, et al. The incidence of inflammatory bowel disease in Northern China: A prospective population-based study[J]. PLoS One, 2014, 9(7): e101296. doi: 10.1371/journal.pone.0101296
|
[5] |
PEYRIN-BIROULET L, SANDBORN W, SANDS BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target[J]. Am J Gastroenterol, 2015, 110(9): 1324-1338. doi: 10.1038/ajg.2015.233
|
[6] |
PEDERSEN J. Inflammatory pathways of importance for management of inflammatory bowel disease[J]. World J Gastroenterol, 2014, 20(1): 64. doi: 10.3748/wjg.v20.i1.64
|
[7] |
MARAFINI I, SEDDA S, DINALLO V, et al. Inflammatory cytokines: From discoveries to therapies in IBD[J]. Expert Opin Biol Ther, 2019, 19: 1207-1217. doi: 10.1080/14712598.2019.1652267
|
[8] |
TORRES J, BONOVAS S, DOHERTY G, et al. ECCO guidelines on therapeutics in Crohn's disease: Medical treatment[J]. J Crohn's Colitis, 2020, 14(1): 4-22. doi: 10.1093/ecco-jcc/jjz180
|
[9] |
TURNER D, RICCIUTO A, LEWIS A, et al. STRIDE-Ⅱ: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD[J]. Gastroenterology, 2021, 160(5): 1570-1583. doi: 10.1053/j.gastro.2020.12.031
|
[10] |
YANG E, PANACCIONE N, WHITMIRE N, et al. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease[J]. Aliment Pharmacol Ther, 2020, 51(11): 1031-1038.
|
[11] |
PRIVITERA G, ONALI S, PUGLIESE D, et al. Dual targeted therapy: A possible option for the management of refractory inflammatory bowel disease[J]. J Crohn's Colitis, 2021, 15(2): 335-339. doi: 10.1093/ecco-jcc/jjaa149
|
[12] |
CASTIGLIONE F, IMPERATORE N, TESTA A, et al. One-year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing[J]. Aliment Pharmacol Ther, 2019, 49(8): 1026-1039.
|